Chimerix, Inc. (NASDAQ:CMRX) CFO Michelle Laspaluto Sells 2,260 Shares of Stock

Chimerix, Inc. (NASDAQ:CMRX) CFO Michelle Laspaluto sold 2,260 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.51, for a total transaction of $10,192.60. Following the sale, the chief financial officer now directly owns 172,977 shares in the company, valued at $780,126.27. The trade was a 1.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michelle Laspaluto also recently made the following trade(s):

• On Thursday, January 30th, Michelle Laspaluto sold 1,015 shares of Chimerix stock. The stock was sold at an average price of $4.11, for a total transaction of $4,171.65.

Chimerix Stock Performance

Shares of NASDAQ:CMRX opened at $4.38 on Friday. Chimerix, Inc. has a 52-week low of $0.75 and a 52-week high of $4.65. The firm has a fifty day moving average of $3.53 and a 200 day moving average of $1.81. The firm has a market capitalization of $393.92 million, a PE ratio of -4.66 and a beta of 0.35.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bender Robert & Associates purchased a new position in Chimerix in the fourth quarter worth $37,000. Susquehanna Fundamental Investments LLC purchased a new position in Chimerix in the fourth quarter worth $59,000. Jane Street Group LLC purchased a new position in Chimerix in the fourth quarter worth $62,000. Diadema Partners LP purchased a new position in Chimerix in the fourth quarter worth $101,000. Finally, Stoneridge Investment Partners LLC grew its position in Chimerix by 22.5% in the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after acquiring an additional 8,134 shares in the last quarter. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Chimerix in a report on Monday, December 30th.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.